A normative perspective on discounting health outcomes.

J Health Serv Res Policy

LSE Health and Social Care, London School of Economics, London, UK.

Published: July 2013

The debate on the appropriate discounting of future outcomes has a long history, with normative deliberation identifying several different considerations. It is suggested here that only two considerations are appropriate in the discounting of health outcomes. First, discounting ought to account for the possibility of future catastrophic events. Second, it is arguably legitimate for democratically elected governments to weight disproportionately their current constituency over future constituencies. It is adjudged that accounting for both of these factors should lead to a maximum annual discount rate of 0.5%, substantially lower than the rates currently recommended by public authorities.

Download full-text PDF

Source
http://dx.doi.org/10.1177/1355819613485671DOI Listing

Publication Analysis

Top Keywords

discounting health
8
health outcomes
8
appropriate discounting
8
normative perspective
4
discounting
4
perspective discounting
4
outcomes debate
4
debate appropriate
4
discounting future
4
future outcomes
4

Similar Publications

Home Urine Dipstick Screening for Bladder and Kidney Cancer in High-Risk Populations in England: A Microsimulation Study of Long-Term Impact and Cost-Effectiveness.

Pharmacoeconomics

January 2025

Sheffield Centre for Health and Related Research (SCHARR), School of Medicine and Population Health, The University of Sheffield, Regent Court, 30 Regent Street, Sheffield, UK.

Background: Testing high-risk populations for non-visible haematuria may enable earlier detection of bladder cancer, potentially decreasing mortality. This research aimed to assess the cost-effectiveness of urine dipstick screening for bladder cancer in high-risk populations in England.

Methods:  A microsimulation model developed in R software was calibrated to national incidence data by age, sex and stage, and validated against mortality data.

View Article and Find Full Text PDF

This study was aimed to evaluate the cost-effectiveness of pembrolizumab with chemotherapy (pembrolizumab combination therapy) and compare it with standard-of-care platinum-based chemotherapy (chemotherapy alone) as a first-line treatment for metastatic nonsquamous NSCLC from the perspective of Taiwan's third-party-payer public health-care system. We used a partitioned survival model with an estimated time horizon of 10 years. The partitioned survival model uses Kaplan-Meier estimates of progression-free and overall survival from the KEYNOTE-189 clinical trial.

View Article and Find Full Text PDF

Cost Effectiveness of Exclusionary EGFR Testing for Taiwanese Patients Newly Diagnosed with Advanced Lung Adenocarcinoma.

Pharmacoeconomics

January 2025

Division of Pulmonology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138 Shengli Road, Tainan, 704, Taiwan.

Background And Objective: Approximately half of lung adenocarcinomas in East Asia harbor epidermal growth factor receptor (EGFR) mutations. EGFR testing followed by tissue-based next-generation sequencing (NGS), upfront tissue-based NGS, and complementary NGS approaches have emerged on the front line to guide personalized therapy. We study the cost effectiveness of exclusionary EGFR testing for Taiwanese patients newly diagnosed with advanced lung adenocarcinoma.

View Article and Find Full Text PDF

Emergence of structures in neuronal network activities.

Sci Rep

January 2025

Department of Medicine (Neurology), McMaster University, Hamilton, ON, L8L 2X2, Canada.

Nonlinear responses of individual neurons are both experimentally established and considered fundamental for the functioning of neuronal circuitry. Consequently, one may envisage the collective dynamics of large networks of neurons exhibiting a large repertoire of nonlinear behaviors. However, an ongoing and central challenge in the modeling of neural dynamics involves the trade-off between tractability and biological realism.

View Article and Find Full Text PDF

We compared the cost-effectiveness of gemcitabine plus nab-paclitaxel (GnP) and modified FOLFIRINOX (mFFX)-standard first-line treatments for metastatic pancreatic cancer in Japan. This retrospective cohort study included patients with metastatic pancreatic cancer treated at the National Cancer Center Hospital East in Japan between December 2013 and February 2017. A partitioned survival model, featuring five mutually exclusive health states, was developed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!